Review



pre randomisation tumour specimen  (Foundation Medicine Inc)


Bioz Verified Symbol Foundation Medicine Inc is a verified supplier
Bioz Manufacturer Symbol Foundation Medicine Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    Foundation Medicine Inc pre randomisation tumour specimen
    Pre Randomisation Tumour Specimen, supplied by Foundation Medicine Inc, used in various techniques. Bioz Stars score: 99/100, based on 2282 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/randomisation/FoundationOne+CDx/pm41422862-70-13-20
    Average 99 stars, based on 2282 article reviews
    pre randomisation tumour specimen - by Bioz Stars, 2026-10
    99/100 stars

    Images

    Related Articles

    Analysis:

    Article Title: Evaluation of MET Detection Methods and Cutoffs in EGFR-Mutated Non-small Cell Lung Cancer Following Disease Progression on Osimertinib in the phase II SAVANNAH study
    Article Snippet: (80% CI 35–60) in 32 patients with EGFR-mutated advanced NSCLC and MET alterations following first-line osimertinib (based on NGS analysis of a tumor biopsy, using standard reported variants from the FoundationOne CDx test). An exploratory analysis of ORR by MET GCN showed a trend towards improved ORR with high MET GCN (≥10; 53%) compared with low MET GCN (<10; 25%; ref (41). In the phase III SACH

    Next-Generation Sequencing:

    Article Title: Evaluation of MET Detection Methods and Cutoffs in EGFR-Mutated Non-small Cell Lung Cancer Following Disease Progression on Osimertinib in the phase II SAVANNAH study
    Article Snippet: (80% CI 35–60) in 32 patients with EGFR-mutated advanced NSCLC and MET alterations following first-line osimertinib (based on NGS analysis of a tumor biopsy, using standard reported variants from the FoundationOne CDx test). An exploratory analysis of ORR by MET GCN showed a trend towards improved ORR with high MET GCN (≥10; 53%) compared with low MET GCN (<10; 25%; ref (41). In the phase III SACH

    Sequencing:

    Article Title: Evaluation of MET Detection Methods and Cutoffs in EGFR-Mutated Non-small Cell Lung Cancer Following Disease Progression on Osimertinib in the phase II SAVANNAH study
    Article Snippet: (80% CI 35–60) in 32 patients with EGFR-mutated advanced NSCLC and MET alterations following first-line osimertinib (based on NGS analysis of a tumor biopsy, using standard reported variants from the FoundationOne CDx test). An exploratory analysis of ORR by MET GCN showed a trend towards improved ORR with high MET GCN (≥10; 53%) compared with low MET GCN (<10; 25%; ref (41). In the phase III SACH

    Tissue:

    Article Title: Evaluation of MET Detection Methods and Cutoffs in EGFR-Mutated Non-small Cell Lung Cancer Following Disease Progression on Osimertinib in the phase II SAVANNAH study
    Article Snippet: (80% CI 35–60) in 32 patients with EGFR-mutated advanced NSCLC and MET alterations following first-line osimertinib (based on NGS analysis of a tumor biopsy, using standard reported variants from the FoundationOne CDx test). An exploratory analysis of ORR by MET GCN showed a trend towards improved ORR with high MET GCN (≥10; 53%) compared with low MET GCN (<10; 25%; ref (41). In the phase III SACH

    Oligomer Restriction:

    Article Title: Evaluation of MET Detection Methods and Cutoffs in EGFR-Mutated Non-small Cell Lung Cancer Following Disease Progression on Osimertinib in the phase II SAVANNAH study
    Article Snippet: (80% CI 35–60) in 32 patients with EGFR-mutated advanced NSCLC and MET alterations following first-line osimertinib (based on NGS analysis of a tumor biopsy, using standard reported variants from the FoundationOne CDx test). An exploratory analysis of ORR by MET GCN showed a trend towards improved ORR with high MET GCN (≥10; 53%) compared with low MET GCN (<10; 25%; ref (41). In the phase III SACH

    Positron Emission Tomography:

    Article Title: Evaluation of MET Detection Methods and Cutoffs in EGFR-Mutated Non-small Cell Lung Cancer Following Disease Progression on Osimertinib in the phase II SAVANNAH study
    Article Snippet: (80% CI 35–60) in 32 patients with EGFR-mutated advanced NSCLC and MET alterations following first-line osimertinib (based on NGS analysis of a tumor biopsy, using standard reported variants from the FoundationOne CDx test). An exploratory analysis of ORR by MET GCN showed a trend towards improved ORR with high MET GCN (≥10; 53%) compared with low MET GCN (<10; 25%; ref (41). In the phase III SACH

    Positron Emission Tomography-Computed Tomography:

    Article Title: Evaluation of MET Detection Methods and Cutoffs in EGFR-Mutated Non-small Cell Lung Cancer Following Disease Progression on Osimertinib in the phase II SAVANNAH study
    Article Snippet: (80% CI 35–60) in 32 patients with EGFR-mutated advanced NSCLC and MET alterations following first-line osimertinib (based on NGS analysis of a tumor biopsy, using standard reported variants from the FoundationOne CDx test). An exploratory analysis of ORR by MET GCN showed a trend towards improved ORR with high MET GCN (≥10; 53%) compared with low MET GCN (<10; 25%; ref (41). In the phase III SACH

    Formalin-fixed Paraffin-Embedded:

    Article Title: Evaluation of MET Detection Methods and Cutoffs in EGFR-Mutated Non-small Cell Lung Cancer Following Disease Progression on Osimertinib in the phase II SAVANNAH study
    Article Snippet: (80% CI 35–60) in 32 patients with EGFR-mutated advanced NSCLC and MET alterations following first-line osimertinib (based on NGS analysis of a tumor biopsy, using standard reported variants from the FoundationOne CDx test). An exploratory analysis of ORR by MET GCN showed a trend towards improved ORR with high MET GCN (≥10; 53%) compared with low MET GCN (<10; 25%; ref (41). In the phase III SACH

    Expressing:

    Article Title: Evaluation of MET Detection Methods and Cutoffs in EGFR-Mutated Non-small Cell Lung Cancer Following Disease Progression on Osimertinib in the phase II SAVANNAH study
    Article Snippet: (80% CI 35–60) in 32 patients with EGFR-mutated advanced NSCLC and MET alterations following first-line osimertinib (based on NGS analysis of a tumor biopsy, using standard reported variants from the FoundationOne CDx test). An exploratory analysis of ORR by MET GCN showed a trend towards improved ORR with high MET GCN (≥10; 53%) compared with low MET GCN (<10; 25%; ref (41). In the phase III SACH

    Selection:

    Article Title: Evaluation of MET Detection Methods and Cutoffs in EGFR-Mutated Non-small Cell Lung Cancer Following Disease Progression on Osimertinib in the phase II SAVANNAH study
    Article Snippet: (80% CI 35–60) in 32 patients with EGFR-mutated advanced NSCLC and MET alterations following first-line osimertinib (based on NGS analysis of a tumor biopsy, using standard reported variants from the FoundationOne CDx test). An exploratory analysis of ORR by MET GCN showed a trend towards improved ORR with high MET GCN (≥10; 53%) compared with low MET GCN (<10; 25%; ref (41). In the phase III SACH



    Similar Products

    pre randomisation tumour specimen  (Foundation Medicine Inc)
    99
    Foundation Medicine Inc pre randomisation tumour specimen
    Pre Randomisation Tumour Specimen, supplied by Foundation Medicine Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/randomisation/FoundationOne+CDx/pm41422862-70-13-20
    Average 99 stars, based on 1 article reviews
    pre randomisation tumour specimen - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier
    randomisation list  (Minitab Inc)
    86
    Minitab Inc randomisation list
    Randomisation List, supplied by Minitab Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/randomisation/computer+generated+list+randomization/pmc13055410-68-35-38
    Average 86 stars, based on 1 article reviews
    randomisation list - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    gcp compliant randomisation system  (Tayside Pharmaceuticals)
    86
    Tayside Pharmaceuticals gcp compliant randomisation system
    AIR-NET adaptive platform trial design summary . The AIR-NET randomised, open-label, multifactorial, multicentre adaptive platform trial has a parallel group design; the trial will open to recruitment with a control arm and the first three treatment arms indicated (oral dose: disulfiram 400 mg once daily; dipyridamole 200 mg twice daily; doxycycline 100 mg once daily. n=42/arm). All three drugs were chosen for their published anti-inflammatory and neutrophil modulatory activities, wide availability, and acceptable safety profiles. Potential participants will be screened for generic eligibility criteria, positive sputum neutrophil elastase lateral flow test and according to arm-specific criteria. Participants will receive 28 days treatment, with a further post-treatment follow-up at day 56. Individual treatment arms will be closed for <t>randomisation</t> when the target for number of participants has been reached, or earlier if advised by the data monitoring committee and closed to follow-up after last participant last visit for that arm. As new possibilities for treatments are identified additional treatment arms will be opened. Any new treatment arms will be submitted as an amendment to the current protocol. Randomisation to the control arm will continue for the duration of the trial. The primary outcome is change from baseline in sputum neutrophil elastase activity, analysis will be performed by pairwise comparison of each treatment arm to concurrent usual care participants, with analysis times varying by arm according to respective last participant last visit.
    Gcp Compliant Randomisation System, supplied by Tayside Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/randomisation/compliant+gcp+randomisation+system/pmc12969703-132-9-12
    Average 86 stars, based on 1 article reviews
    gcp compliant randomisation system - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    randomisation  (STATA Corporation)
    99
    STATA Corporation randomisation
    AIR-NET adaptive platform trial design summary . The AIR-NET randomised, open-label, multifactorial, multicentre adaptive platform trial has a parallel group design; the trial will open to recruitment with a control arm and the first three treatment arms indicated (oral dose: disulfiram 400 mg once daily; dipyridamole 200 mg twice daily; doxycycline 100 mg once daily. n=42/arm). All three drugs were chosen for their published anti-inflammatory and neutrophil modulatory activities, wide availability, and acceptable safety profiles. Potential participants will be screened for generic eligibility criteria, positive sputum neutrophil elastase lateral flow test and according to arm-specific criteria. Participants will receive 28 days treatment, with a further post-treatment follow-up at day 56. Individual treatment arms will be closed for <t>randomisation</t> when the target for number of participants has been reached, or earlier if advised by the data monitoring committee and closed to follow-up after last participant last visit for that arm. As new possibilities for treatments are identified additional treatment arms will be opened. Any new treatment arms will be submitted as an amendment to the current protocol. Randomisation to the control arm will continue for the duration of the trial. The primary outcome is change from baseline in sputum neutrophil elastase activity, analysis will be performed by pairwise comparison of each treatment arm to concurrent usual care participants, with analysis times varying by arm according to respective last participant last visit.
    Randomisation, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/randomisation/STATA+12%2E0/pmc12960068-56-0-4
    Average 99 stars, based on 1 article reviews
    randomisation - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier
    randomisation sequence  (STATA Corporation)
    99
    STATA Corporation randomisation sequence
    AIR-NET adaptive platform trial design summary . The AIR-NET randomised, open-label, multifactorial, multicentre adaptive platform trial has a parallel group design; the trial will open to recruitment with a control arm and the first three treatment arms indicated (oral dose: disulfiram 400 mg once daily; dipyridamole 200 mg twice daily; doxycycline 100 mg once daily. n=42/arm). All three drugs were chosen for their published anti-inflammatory and neutrophil modulatory activities, wide availability, and acceptable safety profiles. Potential participants will be screened for generic eligibility criteria, positive sputum neutrophil elastase lateral flow test and according to arm-specific criteria. Participants will receive 28 days treatment, with a further post-treatment follow-up at day 56. Individual treatment arms will be closed for <t>randomisation</t> when the target for number of participants has been reached, or earlier if advised by the data monitoring committee and closed to follow-up after last participant last visit for that arm. As new possibilities for treatments are identified additional treatment arms will be opened. Any new treatment arms will be submitted as an amendment to the current protocol. Randomisation to the control arm will continue for the duration of the trial. The primary outcome is change from baseline in sputum neutrophil elastase activity, analysis will be performed by pairwise comparison of each treatment arm to concurrent usual care participants, with analysis times varying by arm according to respective last participant last visit.
    Randomisation Sequence, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/randomisation/STATA+15%2E0/pm41549406-39-1-6
    Average 99 stars, based on 1 article reviews
    randomisation sequence - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier
    randomisation list  (Novartis)
    86
    Novartis randomisation list
    AIR-NET adaptive platform trial design summary . The AIR-NET randomised, open-label, multifactorial, multicentre adaptive platform trial has a parallel group design; the trial will open to recruitment with a control arm and the first three treatment arms indicated (oral dose: disulfiram 400 mg once daily; dipyridamole 200 mg twice daily; doxycycline 100 mg once daily. n=42/arm). All three drugs were chosen for their published anti-inflammatory and neutrophil modulatory activities, wide availability, and acceptable safety profiles. Potential participants will be screened for generic eligibility criteria, positive sputum neutrophil elastase lateral flow test and according to arm-specific criteria. Participants will receive 28 days treatment, with a further post-treatment follow-up at day 56. Individual treatment arms will be closed for <t>randomisation</t> when the target for number of participants has been reached, or earlier if advised by the data monitoring committee and closed to follow-up after last participant last visit for that arm. As new possibilities for treatments are identified additional treatment arms will be opened. Any new treatment arms will be submitted as an amendment to the current protocol. Randomisation to the control arm will continue for the duration of the trial. The primary outcome is change from baseline in sputum neutrophil elastase activity, analysis will be performed by pairwise comparison of each treatment arm to concurrent usual care participants, with analysis times varying by arm according to respective last participant last visit.
    Randomisation List, supplied by Novartis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/randomisation/list+randomisation/10__1002_slash_14651858__cd009885__pub4-5010-38-10
    Average 86 stars, based on 1 article reviews
    randomisation list - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    tayside randomisation system trust  (Tayside Pharmaceuticals)
    86
    Tayside Pharmaceuticals tayside randomisation system trust
    AIR-NET adaptive platform trial design summary . The AIR-NET randomised, open-label, multifactorial, multicentre adaptive platform trial has a parallel group design; the trial will open to recruitment with a control arm and the first three treatment arms indicated (oral dose: disulfiram 400 mg once daily; dipyridamole 200 mg twice daily; doxycycline 100 mg once daily. n=42/arm). All three drugs were chosen for their published anti-inflammatory and neutrophil modulatory activities, wide availability, and acceptable safety profiles. Potential participants will be screened for generic eligibility criteria, positive sputum neutrophil elastase lateral flow test and according to arm-specific criteria. Participants will receive 28 days treatment, with a further post-treatment follow-up at day 56. Individual treatment arms will be closed for <t>randomisation</t> when the target for number of participants has been reached, or earlier if advised by the data monitoring committee and closed to follow-up after last participant last visit for that arm. As new possibilities for treatments are identified additional treatment arms will be opened. Any new treatment arms will be submitted as an amendment to the current protocol. Randomisation to the control arm will continue for the duration of the trial. The primary outcome is change from baseline in sputum neutrophil elastase activity, analysis will be performed by pairwise comparison of each treatment arm to concurrent usual care participants, with analysis times varying by arm according to respective last participant last visit.
    Tayside Randomisation System Trust, supplied by Tayside Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/randomisation/compliant+gcp+randomisation+system/10__1183_slash_23120541__00719___2025-296-236-236
    Average 86 stars, based on 1 article reviews
    tayside randomisation system trust - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    randomisation system  (Tayside Pharmaceuticals)
    86
    Tayside Pharmaceuticals randomisation system
    AIR-NET adaptive platform trial design summary . The AIR-NET randomised, open-label, multifactorial, multicentre adaptive platform trial has a parallel group design; the trial will open to recruitment with a control arm and the first three treatment arms indicated (oral dose: disulfiram 400 mg once daily; dipyridamole 200 mg twice daily; doxycycline 100 mg once daily. n=42/arm). All three drugs were chosen for their published anti-inflammatory and neutrophil modulatory activities, wide availability, and acceptable safety profiles. Potential participants will be screened for generic eligibility criteria, positive sputum neutrophil elastase lateral flow test and according to arm-specific criteria. Participants will receive 28 days treatment, with a further post-treatment follow-up at day 56. Individual treatment arms will be closed for <t>randomisation</t> when the target for number of participants has been reached, or earlier if advised by the data monitoring committee and closed to follow-up after last participant last visit for that arm. As new possibilities for treatments are identified additional treatment arms will be opened. Any new treatment arms will be submitted as an amendment to the current protocol. Randomisation to the control arm will continue for the duration of the trial. The primary outcome is change from baseline in sputum neutrophil elastase activity, analysis will be performed by pairwise comparison of each treatment arm to concurrent usual care participants, with analysis times varying by arm according to respective last participant last visit.
    Randomisation System, supplied by Tayside Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/randomisation/compliant+gcp+randomisation+system/10__1183_slash_23120541__00719___2025-209-12-14
    Average 86 stars, based on 1 article reviews
    randomisation system - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    � fsc corrected fsc unmasked fsc masked fsc phase randomised 0 75xk10 peg pbs b dc  (Thermo Fisher)
    99
    Thermo Fisher � fsc corrected fsc unmasked fsc masked fsc phase randomised 0 75xk10 peg pbs b dc
    AIR-NET adaptive platform trial design summary . The AIR-NET randomised, open-label, multifactorial, multicentre adaptive platform trial has a parallel group design; the trial will open to recruitment with a control arm and the first three treatment arms indicated (oral dose: disulfiram 400 mg once daily; dipyridamole 200 mg twice daily; doxycycline 100 mg once daily. n=42/arm). All three drugs were chosen for their published anti-inflammatory and neutrophil modulatory activities, wide availability, and acceptable safety profiles. Potential participants will be screened for generic eligibility criteria, positive sputum neutrophil elastase lateral flow test and according to arm-specific criteria. Participants will receive 28 days treatment, with a further post-treatment follow-up at day 56. Individual treatment arms will be closed for <t>randomisation</t> when the target for number of participants has been reached, or earlier if advised by the data monitoring committee and closed to follow-up after last participant last visit for that arm. As new possibilities for treatments are identified additional treatment arms will be opened. Any new treatment arms will be submitted as an amendment to the current protocol. Randomisation to the control arm will continue for the duration of the trial. The primary outcome is change from baseline in sputum neutrophil elastase activity, analysis will be performed by pairwise comparison of each treatment arm to concurrent usual care participants, with analysis times varying by arm according to respective last participant last visit.
    � Fsc Corrected Fsc Unmasked Fsc Masked Fsc Phase Randomised 0 75xk10 Peg Pbs B Dc, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/randomisation/PHOSPHATE+BUFFERED+SALINE+PBS/pm33724780__nn0c10137_si_001-14-69-109
    Average 99 stars, based on 1 article reviews
    � fsc corrected fsc unmasked fsc masked fsc phase randomised 0 75xk10 peg pbs b dc - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    AIR-NET adaptive platform trial design summary . The AIR-NET randomised, open-label, multifactorial, multicentre adaptive platform trial has a parallel group design; the trial will open to recruitment with a control arm and the first three treatment arms indicated (oral dose: disulfiram 400 mg once daily; dipyridamole 200 mg twice daily; doxycycline 100 mg once daily. n=42/arm). All three drugs were chosen for their published anti-inflammatory and neutrophil modulatory activities, wide availability, and acceptable safety profiles. Potential participants will be screened for generic eligibility criteria, positive sputum neutrophil elastase lateral flow test and according to arm-specific criteria. Participants will receive 28 days treatment, with a further post-treatment follow-up at day 56. Individual treatment arms will be closed for randomisation when the target for number of participants has been reached, or earlier if advised by the data monitoring committee and closed to follow-up after last participant last visit for that arm. As new possibilities for treatments are identified additional treatment arms will be opened. Any new treatment arms will be submitted as an amendment to the current protocol. Randomisation to the control arm will continue for the duration of the trial. The primary outcome is change from baseline in sputum neutrophil elastase activity, analysis will be performed by pairwise comparison of each treatment arm to concurrent usual care participants, with analysis times varying by arm according to respective last participant last visit.

    Journal: ERJ Open Research

    Article Title: Design and rationale of the AIR-NET trial: a randomised, open-label, multifactorial, multicentre, adaptive platform trial using a range of repurposed anti-inflammatory treatments to improve outcomes in patients with bronchiectasis within the EMBARC clinical research network

    doi: 10.1183/23120541.00719-2025

    Figure Lengend Snippet: AIR-NET adaptive platform trial design summary . The AIR-NET randomised, open-label, multifactorial, multicentre adaptive platform trial has a parallel group design; the trial will open to recruitment with a control arm and the first three treatment arms indicated (oral dose: disulfiram 400 mg once daily; dipyridamole 200 mg twice daily; doxycycline 100 mg once daily. n=42/arm). All three drugs were chosen for their published anti-inflammatory and neutrophil modulatory activities, wide availability, and acceptable safety profiles. Potential participants will be screened for generic eligibility criteria, positive sputum neutrophil elastase lateral flow test and according to arm-specific criteria. Participants will receive 28 days treatment, with a further post-treatment follow-up at day 56. Individual treatment arms will be closed for randomisation when the target for number of participants has been reached, or earlier if advised by the data monitoring committee and closed to follow-up after last participant last visit for that arm. As new possibilities for treatments are identified additional treatment arms will be opened. Any new treatment arms will be submitted as an amendment to the current protocol. Randomisation to the control arm will continue for the duration of the trial. The primary outcome is change from baseline in sputum neutrophil elastase activity, analysis will be performed by pairwise comparison of each treatment arm to concurrent usual care participants, with analysis times varying by arm according to respective last participant last visit.

    Article Snippet: Randomisation will be done via the centrally controlled, web-based, GCP-compliant randomisation system, Tayside Randomisation System (TRuST), run by the Health Informatics Centre (University of Dundee), with allocation provided via email.

    Techniques: Control, Activity Assay, Comparison